Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Diacomit

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

ICR researchers identify potential treatment approach for acute myeloid leukaemia

More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

- PMLiVE

ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients

More than 130,000 patients are treated with radiotherapy on the NHS every year

- PMLiVE

ICR researchers identify new drug target for advanced prostate cancer patients

The team estimates that around 10% of patients have high levels of the BCL2 protein

- PMLiVE

Breast cancer drug found to help slow growth of rare childhood brain tumour

Researchers discovered that targeting the CDK6 protein could make tumour cells vulnerable to treatment

- PMLiVE

UK study reveals previously unknown genetic causes of colorectal cancer

The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

- PMLiVE

Study shows epilepsy drug could tackle chemotherapy-resistance in stomach cancer

Clinical trials have been launched to evaluate whether Diacomit causes chemotherapy to work again

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links